Core Insights - Shanghai Weike Biotechnology Co., Ltd. has completed nearly 100 million RMB in Series A financing [1] - The financing round was led by Shenzhen Capital Group and followed by Xichuang Investment, with Fenghe Capital serving as the exclusive financial advisor [1] - The funds will accelerate the establishment of a cell and gene therapy (CGT) evaluation laboratory in the U.S., CGT evaluation services, clinical services, and the expansion of overseas biobreeding services [1]

Group 1 - Weike Bio has recently completed nearly 100 million yuan in Series A financing, led by Shenzhen Capital Group and followed by Xichuang Investment, with funds primarily aimed at accelerating the establishment of a CGT safety evaluation center in the U.S. and expanding overseas services [1] - The company specializes in providing CRO services based on safety evaluation for cell and gene therapy (CGT) drugs, with a core team from Heidelberg University and the German National Cancer Research Center, possessing extensive experience in the CGT safety evaluation field [1][2] - As of now, Weike Bio has served over 70 pharmaceutical companies and research institutions, covering more than 100 drug pipelines, and has supported several companies in achieving dual submissions in China and the U.S., with the fastest approval for market launch [3] Group 2 - The current stage of the CGT industry in China is still in its early phase, with the safety evaluation market for related drugs also at a nascent stage, posing challenges for Weike Bio as a startup to enter the supply chain of major downstream companies [2] - Weike Bio has established a comprehensive technical platform for biological breeding, synthetic biology, and early diagnosis and screening, having set up a subsidiary in Qingdao to serve hundreds of enterprises and research clients in the biological breeding sector [3]